Skip to main content
. 2022 Nov 25;14(23):5820. doi: 10.3390/cancers14235820

Figure 4.

Figure 4

Therapeutic efficacy of Toca 511 and 5-FC therapy in subcutaneous tumor models of A549 human lung cancer and Ex-3LL murine lung cancer. Dorsal flank tumors were established and Toca 511 infection was initiated starting from an initial transduction level of 1% (n = 5/group). Uninfected tumors served as negative controls (‘No vector’). Data are shown as the mean ± SD. (A) Tumor growth curves for subcutaneous A549 human lung cancer xenograft models. Prodrug (5-FC) or saline vehicle (PBS) treatments were administered daily (500 mg/kg i.p.) for 7 consecutive days every other week, starting from day 21 post-tumor establishment (indicated by arrows); * p = 0.0051. (B) Tumor growth curves for subcutaneous Ex-3LL murine lung cancer tumor models in immunocompetent syngeneic mice. As above, prodrug (5-FC) or saline vehicle (PBS) treatments were administered daily (500 mg/kg i.p.) for 7 consecutive days every other week, starting from day 14 post-tumor establishment (arrows); ** p = 0.0018.